Inhaled corticosteroids and pneumonia in chronic obstructive pulmonary disease

The Lancet Respiratory Medicine

Volumn 2, Issue 11, 2014, Pages 919-932

  Finney, Lydia ^a   Berry, Matthew ^a   Singanayagam, Aran ^a   Elkin, Sarah L ^a   Johnston, Sebastian L ^a   Mallia, Patrick ^a  

^a NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE PLUS FORMOTEROL; CORTICOSTEROID; DEXAMETHASONE; FLUTICASONE FUROATE PLUS VILANTEROL; FLUTICASONE PROPIONATE; FLUTICASONE PROPIONATE PLUS SALMETEROL; PLACEBO; SALMETEROL; TIOTROPIUM BROMIDE;

ASTHMA; BACTERIAL INFECTION; BACTERIUM ADHERENCE; BODY MASS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL (TOPIC); CYTOKINE PRODUCTION; DIAGNOSTIC ERROR; DISEASE EXACERBATION; DRUG DOSE REDUCTION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSPNEA; EOSINOPHILIA; FORCED EXPIRATORY VOLUME; HOSPITAL ADMISSION; HUMAN; INFECTION SENSITIVITY; LOW DRUG DOSE; MACROPHAGE ACTIVATION; MONOTHERAPY; MORTALITY; NEUTROPHIL CHEMOTAXIS; NONHUMAN; OBSERVATIONAL STUDY; PATIENT DROPOUTS; PHAGOCYTOSIS; PNEUMONIA; RESPIRATORY TRACT INFECTION; RESPIRATORY TRACT INFLAMMATION; REVIEW; THORAX RADIOGRAPHY; ANIMAL; CHEMICALLY INDUCED; COMPLICATION; EPIDEMIOLOGY; IMMUNOLOGY; INHALATIONAL DRUG ADMINISTRATION; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RISK FACTOR;

ADMINISTRATION, INHALATION; ADRENAL CORTEX HORMONES; ANIMALS; CLINICAL TRIALS AS TOPIC; CONFOUNDING FACTORS (EPIDEMIOLOGY); HUMANS; OBSERVATIONAL STUDIES AS TOPIC; PNEUMONIA; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RESPIRATORY TRACT INFECTIONS; RISK FACTORS;

EID: 84918840018     PISSN: 22132600     EISSN: 22132619     Source Type: Journal    
DOI: 10.1016/S2213-2600(14)70169-9     Document Type: Review

References (128)

1. Vestbo J, Hurd SS, Agustí AG, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2013, 187:347-365.
2. Farr BM, Woodhead MA, Macfarlane JT, et al. Risk factors for community-acquired pneumonia diagnosed by general practitioners in the community. Respir Med 2000, 94:422-427.
3. Martinez FD, Vercelli D Asthma. Lancet 2013, 382:1360-1372.
4. Decramer M1, Janssens W, Miravitlles M Chronic obstructive pulmonary disease. Lancet 2012, 379:1341-1351.
5. Burge PS, Calverley PM, Jones PW, Spencer S, Anderson JA, Maslen TK Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: The ISOLDE trial. BMJ 2000, 320:1297-1303.
6. Calverley PM, Anderson JA, Celli B, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007, 356:775-789. the TORCH investigators.
7. Burgel PR, Deslée G, Jebrak G, et al. Real-life use of inhaled corticosteroids in COPD patients versus the GOLD proposals: a paradigm shift in GOLD 2011?. Eur Respir J 2014, 43:1201-1203. the Initiatives BPCO scientific committee.
8. Thomas M, Radwan A, Stonham C, Marshall S COPD exacerbation frequency, pharmacotherapy and resource use: an observational study in UK primary care. COPD 2014, 11:300-309.
9. Crim C, Calverley PM, Anderson JA, et al. Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results. Eur Respir J 2009, 34:641-647.
10. Calverley PM, Stockley RA, Seemungal TA, et al. Reported pneumonia in patients with COPD: findings from the INSPIRE study. Chest 2011, 139:505-512. the Investigating New Standards for Prophylaxis in Reduction of Exacerbations (INSPIRE) Investigators.
11. Kardos P, Wencker M, Glaab T, Vogelmeier C Impact of salmeterol/fluticasone propionate versus salmeterol on exacerbations in severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007, 175:144-149.
12. Anzueto A, Ferguson GT, Feldman G, et al. Effect of fluticasone propionate/salmeterol (250/50) on COPD exacerbations and impact on patient outcomes. COPD 2009, 6:320-329.
13. Ferguson GT, Anzueto A, Fei R, Emmett A, Knobil K, Kalberg C Effect of fluticasone propionate/salmeterol (250/50 microg) or salmeterol (50 microg) on COPD exacerbations. Respir Med 2008, 102:1099-1108.
14. Kew KM, Seniukovich A Inhaled steroids and risk of pneumonia for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2014, 3. CD010115.
15. Tashkin DP, Rennard SI, Martin P, et al. Efficacy and safety of budesonide and formoterol in one pressurized metered-dose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease: results of a 6-month randomized clinical trial. Drugs 2008, 68:1975-2000.
16. Rennard SI, Tashkin DP, McElhattan J, et al. Efficacy and tolerability of budesonide/formoterol in one hydrofluoroalkane pressurized metered-dose inhaler in patients with chronic obstructive pulmonary disease: results from a 1-year randomized controlled clinical trial. Drugs 2009, 69:549-565.
17. Welte T, Miravitlles M, Hernandez P, et al. Efficacy and tolerability of budesonide/formoterol added to tiotropium in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2009, 180:741-750.
18. Sharafkhaneh A, Southard JG, Goldman M, Uryniak T, Martin UJ Effect of budesonide/formoterol pMDI on COPD exacerbations: a double-blind, randomized study. Respir Med 2012, 106:257-268.
19. Suissa S, Patenaude V, Lapi F, Ernst P Inhaled corticosteroids in COPD and the risk of serious pneumonia. Thorax 2013, 68:1029-1036.
20. Ernst P, Gonzalez AV, Brassard P, Suissa S Inhaled corticosteroid use in chronic obstructive pulmonary disease and the risk of hospitalization for pneumonia. Am J Respir Crit Care Med 2007, 176:162-166.
21. Thornton Snider J, Luna Y, Wong KS, et al. Inhaled corticosteroids and the risk of pneumonia in Medicare patients with COPD. Curr Med Res Opin 2012, 28:1959-1967.
22. Joo MJ, Au DH, Fitzgibbon ML, Lee TA Inhaled corticosteroids and risk of pneumonia in newly diagnosed COPD. Respir Med 2010, 104:246-252.
23. Yawn BP, Li Y, Tian H, Zhang J, Arcona S, Kahler KH Inhaled corticosteroid use in patients with chronic obstructive pulmonary disease and the risk of pneumonia: a retrospective claims data analysis. Int J Chron Obstruct Pulmon Dis 2013, 8:295-304.
24. Almirall J, Bolíbar I, Serra-Prat M, et al. Inhaled drugs as risk factors for community-acquired pneumonia. Eur Respir J 2010, 36:1080-1087. the Community-Acquired Pneumonia in Catalan Countries.
25. Dransfield MT, Bourbeau J, Jones PW, et al. Once-daily inhaled fluticasone furoate and vilanterol versus vilanterol only for prevention of exacerbations of COPD: two replicate double-blind, parallel-group, randomised controlled trials. Lancet Respir Med 2013, 1:210-223.
26. Drummond MB, Dasenbrook EC, Pitz MW, Murphy DJ, Fan E Inhaled corticosteroids in patients with stable chronic obstructive pulmonary disease: a systematic review and meta-analysis. JAMA 2008, 300:2407-2416.
27. Singh S, Amin AV, Loke YK Long-term use of inhaled corticosteroids and the risk of pneumonia in chronic obstructive pulmonary disease: a meta-analysis. Arch Intern Med 2009, 169:219-229.
28. Singh S, Loke YK Risk of pneumonia associated with long-term use of inhaled corticosteroids in chronic obstructive pulmonary disease: a critical review and update. Curr Opin Pulm Med 2010, 16:118-122.
29. Müllerova H, Chigbo C, Hagan GW, et al. The natural history of community-acquired pneumonia in COPD patients: a population database analysis. Respir Med 2012, 106:1124-1133.
30. Mapel D, Schum M, Yood M, Brown J, Miller D, Davis K Pneumonia among COPD patients using inhaled corticosteroids and long-acting bronchodilators. Prim Care Respir J 2010, 19:109-117.
31. Festic E, Bansal V, Gajic O, Lee AS Prehospital use of inhaled corticosteroids and point prevalence of pneumonia at the time of hospital admission: secondary analysis of a multicenter cohort study. Mayo Clin Proc 2014, 89:154-162. the United States Critical Illness and Injury Trials Group: Lung Injury Prevention Study Investigators (USCIITG-LIPS).
32. Restrepo MI, Mortensen EM, Pugh JA, Anzueto A COPD is associated with increased mortality in patients with community-acquired pneumonia. Eur Respir J 2006, 28:346-351.
33. Chen D, Restrepo MI, Fine MJ, et al. Observational study of inhaled corticosteroids on outcomes for COPD patients with pneumonia. Am J Respir Crit Care Med 2011, 184:312-316.
34. Malo de Molina R, Mortensen EM, Restrepo MI, Copeland LA, Pugh MJ, Anzueto A Inhaled corticosteroid use is associated with lower mortality for subjects with COPD and hospitalised with pneumonia. Eur Respir J 2010, 36:751-757.
35. Singanayagam A, Chalmers JD, Akram AR, Hill AT Impact of inhaled corticosteroid use on outcome in COPD patients admitted with pneumonia. Eur Respir J 2011, 38:36-41.
36. Almirall J, Bolíbar I, Serra-Prat M, et al. Relationship between the use of inhaled steroids for chronic respiratory diseases and early outcomes in community-acquired pneumonia. PLoS One 2013, 8:e73271. the Community-Acquired Pneumonia in Catalan Countries (PACAP).
37. Loke YK, Kwok CS, Wong JM, Sankaran P, Myint PK Chronic obstructive pulmonary disease and mortality from pneumonia: meta-analysis. Int J Clin Pract 2013, 67:477-487.
38. Myint PK, Lowe D, Stone RA, Buckingham RJ, Roberts CMUK U.K. National COPD Resources and Outcomes Project 2008: patients with chronic obstructive pulmonary disease exacerbations who present with radiological pneumonia have worse outcome compared to those with non-pneumonic chronic obstructive pulmonary disease exacerbations. Respiration 2011, 82:320-327.
39. Steer J, Gibson J, Bourke SC The DECAF Score: predicting hospital mortality in exacerbations of chronic obstructive pulmonary disease. Thorax 2012, 67:970-976.
40. Roche N, Zureik M, Soussan D, Neukirch F, Perrotin D Predictors of outcomes in COPD exacerbation cases presenting to the emergency department. Eur Respir J 2008, 32:953-961. the Urgence BPCO (COPD Emergency) Scientific Committee.
41. Huerta A, Crisafulli E, Menéndez R, et al. Pneumonic and nonpneumonic exacerbations of COPD: inflammatory response and clinical characteristics. Chest 2013, 144:1134-1142.
42. Lieberman D, Shvartzman P, Korsonsky I, Lieberman D Diagnosis of ambulatory community-acquired pneumonia. Comparison of clinical assessment versus chest X-ray. Scand J Prim Health Care 2003, 21:57-60.
43. van Vugt SF, Verheij TJ, de Jong PA, et al. Diagnosing pneumonia in patients with acute cough: clinical judgment compared to chest radiography. Eur Respir J 2013, 42:1076-1082. the GRACE Project Group.
44. Janson C, Larsson K, Lisspers KH, et al. Pneumonia and pneumonia related mortality in patients with COPD treated with fixed combinations of inhaled corticosteroid and long acting β2 agonist: observational matched cohort study (PATHOS). BMJ 2013, 346:f3306.
45. van de Garde EM, Oosterheert JJ, Bonten M, Kaplan RC, Leufkens HG International classification of diseases codes showed modest sensitivity for detecting community-acquired pneumonia. J Clin Epidemiol 2007, 60:834-838.
46. Kanwar M, Brar N, Khatib R, Fakih MG Misdiagnosis of community-acquired pneumonia and inappropriate utilization of antibiotics: side effects of the 4-h antibiotic administration rule. Chest 2007, 131:1865-1869.
47. Torres A, Peetermans WE, Viegi G, Blasi F Risk factors for community-acquired pneumonia in adults in Europe: a literature review. Thorax 2013, 68:1057-1065.
48. Schnell K, Weiss CO, Lee T, et al. The prevalence of clinically-relevant comorbid conditions in patients with physician-diagnosed COPD: a cross-sectional study using data from NHANES 1999-2008. BMC Pulm Med 2012, 12:26.
49. Snijders D, Daniels JM, de Graaff CS, van der Werf TS, Boersma WG Efficacy of corticosteroids in community-acquired pneumonia: a randomized double-blinded clinical trial. Am J Respir Crit Care Med 2010, 181:975-982.
50. Confalonieri M, Annane D, Antonaglia C, Santagiuliana M, Borriello EM, Meduri GU Is prolonged low-dose glucocorticoid treatment beneficial in community-acquired pneumonia?. Curr Infect Dis Rep 2013, 15:158-166.
51. Sellares J, López-Giraldo A, Lucena C, et al. Influence of previous use of inhaled corticoids on the development of pleural effusion in community-acquired pneumonia. Am J Respir Crit Care Med 2013, 187:1241-1248.
52. Llor C, Moragas A, Hernández S, Bayona C, Miravitlles M Efficacy of antibiotic therapy for acute exacerbations of mild to moderate chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2012, 186:716-723.
53. Singanayagam A, Chalmers JD Budesonide and risk of pneumonia. Lancet 2009, 374:2050. author reply 2051-52.
54. Garcha DS, Thurston SJ, Patel AR, et al. Changes in prevalence and load of airway bacteria using quantitative PCR in stable and exacerbated COPD. Thorax 2012, 67:1075-1080.
55. Vestbo J, Anderson JA, Calverley PM, et al. Bias due to withdrawal in long-term randomised trials in COPD: evidence from the TORCH study. Clin Respir J 2011, 5:44-49.
56. Jenkins CR, Jones PW, Calverley PM, et al. Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo-controlled TORCH study. Respir Res 2009, 10:59.
57. Szafranski W, Cukier A, Ramirez A, et al. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. Eur Respir J 2003, 21:74-81.
58. Calverley PM, Boonsawat W, Cseke Z, Zhong N, Peterson S, Olsson H Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. Eur Respir J 2003, 22:912-919.
59. Calverley PM, Spencer S, Willits L, Burge PS, Jones PW Withdrawal from treatment as an outcome in the ISOLDE study of COPD. Chest 2003, 124:1350-1356. the IOSLDE Study Group.
60. Papi A, Bellettato CM, Braccioni F, et al. Infections and airway inflammation in chronic obstructive pulmonary disease severe exacerbations. Am J Respir Crit Care Med 2006, 173:1114-1121.
61. Jennings LC, Anderson TP, Beynon KA, et al. Incidence and characteristics of viral community-acquired pneumonia in adults. Thorax 2008, 63:42-48.
62. Hackx M, Ghaye B, Coche E, Muylem AV, Gevenois PA Severe COPD exacerbation: CT features. COPD 2014, published online June 10. 10.3109/15412555.2014.903916.
63. Okada F, Ando Y, Matsushita S, et al. Thin-section CT findings of patients with acute Streptococcus pneumoniae pneumonia with and without concurrent infection. Br J Radiol 2012, 85:e357-e364.
64. Singh D, Edwards L, Tal-Singer R, Rennard S Sputum neutrophils as a biomarker in COPD: findings from the ECLIPSE study. Respir Res 2010, 11:77.
65. Forsslund H, Mikko M, Karimi R, et al. Distribution of T-cell subsets in BAL fluid of patients with mild to moderate COPD depends on current smoking status and not airway obstruction. Chest 2014, 145:711-722.
66. Taylor AE, Finney-Hayward TK, Quint JK, et al. Defective macrophage phagocytosis of bacteria in COPD. Eur Respir J 2010, 35:1039-1047.
67. Harvey CJ, Thimmulappa RK, Sethi S, et al. Targeting Nrf2 signaling improves bacterial clearance by alveolar macrophages in patients with COPD and in a mouse model. Sci Transl Med 2011, 3:78ra32.
68. Armstrong J, Sargent C, Singh D Glucocorticoid sensitivity of lipopolysaccharide-stimulated chronic obstructive pulmonary disease alveolar macrophages. Clin Exp Immunol 2009, 158:74-83.
69. Armstrong J, Harbron C, Lea S, et al. Synergistic effects of p38 mitogen-activated protein kinase inhibition with a corticosteroid in alveolar macrophages from patients with chronic obstructive pulmonary disease. J Pharmacol Exp Ther 2011, 338:732-740.
70. Berenson CS, Kruzel RL, Eberhardt E, et al. Impaired innate immune alveolar macrophage response and the predilection for COPD exacerbations. Thorax 2014, published online March 31. 10.1136/thoraxjnl-2013-203669.
71. Patterson CM, Morrison RL, D'Souza A, Teng XS, Happel KI Inhaled fluticasone propionate impairs pulmonary clearance of Klebsiella pneumoniae in mice. Respir Res 2012, 13:40.
72. Donnelly LE, Tudhope SJ, Fenwick PS, Barnes PJ Effects of formoterol and salmeterol on cytokine release from monocyte-derived macrophages. Eur Respir J 2010, 36:178-186.
73. Knobloch J, Hag H, Jungck D, Urban K, Koch A Resveratrol impairs the release of steroid-resistant cytokines from bacterial endotoxin-exposed alveolar macrophages in chronic obstructive pulmonary disease. Basic Clin Pharmacol Toxicol 2011, 109:138-143.
74. Marshall BG, Wangoo A, Harrison LI, Young DB, Shaw RJ Tumour necrosis factor-alpha production in human alveolar macrophages: modulation by inhaled corticosteroid. Eur Respir J 2000, 15:764-770.
75. Ek A, Larsson K, Siljerud S, Palmberg L Fluticasone and budesonide inhibit cytokine release in human lung epithelial cells and alveolar macrophages. Allergy 1999, 54:691-699.
76. Miller-Larsson A, Jansson P, Runström A, Brattsand R Prolonged airway activity and improved selectivity of budesonide possibly due to esterification. Am J Respir Crit Care Med 2000, 162:1455-1461.
77. van de Garde MD, Martinez FO, Melgert BN, Hylkema MN, Jonkers RE, Hamann J Chronic exposure to glucocorticoids shapes gene expression and modulates innate and adaptive activation pathways in macrophages with distinct changes in leukocyte attraction. J Immunol 2014, 192:1196-1208.
78. Cosio BG, Tsaprouni L, Ito K, Jazrawi E, Adcock IM, Barnes PJ Theophylline restores histone deacetylase activity and steroid responses in COPD macrophages. J Exp Med 2004, 200:689-695.
79. Ratcliffe MJ, Dougall IG Comparison of the anti-inflammatory effects of Cilomilast, Budesonide and a p38 Mitogen activated protein kinase inhibitor in COPD lung tissue macrophages. BMC Pharmacol Toxicol 2012, 13:15.
80. Plumb J, Robinson L, Lea S, et al. Evaluation of glucocorticoid receptor function in COPD lung macrophages using beclomethasone-17-monopropionate. PLoS One 2013, 8:e64257.
81. Haque R, Hakim A, Moodley T, et al. Inhaled long-acting β2 agonists enhance glucocorticoid receptor nuclear translocation and efficacy in sputum macrophages in COPD. J Allergy Clin Immunol 2013, 132:1166-1173.
82. Chana KK, Fenwick PS, Nicholson AG, Barnes PJ, Donnelly LE Identification of a distinct glucocorticosteroid-insensitive pulmonary macrophage phenotype in patients with chronic obstructive pulmonary disease. J Allergy Clin Immunol 2014, 133:207-216. e11.
83. Prieto A, Reyes E, Bernstein ED, et al. Defective natural killer and phagocytic activities in chronic obstructive pulmonary disease are restored by glycophosphopeptical (inmunoferón). Am J Respir Crit Care Med 2001, 163:1578-1583.
84. Müns G, Rubinstein I, Bergmann KC Phagocytosis and oxidative burst of blood phagocytes in chronic obstructive airway disease. Scand J Infect Dis 1995, 27:369-373.
85. Mortaz E, Rad MV, Johnson M, Raats D, Nijkamp FP, Folkerts G Salmeterol with fluticasone enhances the suppression of IL-8 release and increases the translocation of glucocorticoid receptor by human neutrophils stimulated with cigarette smoke. J Mol Med (Berl) 2008, 86:1045-1056.
86. Meliton AY, Munoz NM, Zhu X, Leff AR Attenuated translocation of group IVa phospholipase A2 and up-regulated annexin-1 synthesis by glucocorticoid blocks beta 2-integrin adhesion in neutrophils. J Leukoc Biol 2008, 83:344-351.
87. Lapponi MJ, Carestia A, Landoni VI, et al. Regulation of neutrophil extracellular trap formation by anti-inflammatory drugs. J Pharmacol Exp Ther 2013, 345:430-437.
88. Plumb J, Gaffey K, Kane B, et al. Reduced glucocorticoid receptor expression and function in airway neutrophils. Int Immunopharmacol 2012, 12:26-33.
89. Zhang X, Moilanen E, Kankaanranta H Beclomethasone, budesonide and fluticasone propionate inhibit human neutrophil apoptosis. Eur J Pharmacol 2001, 431:365-371.
90. Perttunen H, Moilanen E, Zhang X, Barnes PJ, Kankaanranta H Beta2-agonists potentiate corticosteroid-induced neutrophil survival. COPD 2008, 5:163-169.
91. Wang P, Wang X, Yang X, Liu Z, Wu M, Li G Budesonide suppresses pulmonary antibacterial host defense by down-regulating cathelicidin-related antimicrobial peptide in allergic inflammation mice and in lung epithelial cells. BMC Immunol 2013, 14:7.
92. Dowling RB, Johnson M, Cole PJ, Wilson R Effect of fluticasone propionate and salmeterol on Pseudomonas aeruginosa infection of the respiratory mucosa in vitro. Eur Respir J 1999, 14:363-369.
93. Barbier M, Agustí A, Albertí S Fluticasone propionate reduces bacterial airway epithelial invasion. Eur Respir J 2008, 32:1283-1288.
94. Zhang L, Prietsch SO, Mendes AP, et al. Inhaled corticosteroids increase the risk of oropharyngeal colonization by Streptococcus pneumoniae in children with asthma. Respirology 2013, 18:272-277.
95. Goggin R, Jardeleza C, Wormald PJ, Vreugde S Corticosteroids directly reduce Staphylococcus aureus biofilm growth: an in vitro study. Laryngoscope 2014, 124:602-607.
96. Marin A, Garcia-Aymerich J, Sauleda J, et al. Effect of bronchial colonisation on airway and systemic inflammation in stable COPD. COPD 2012, 9:121-130. the PAC-COPD Study Group.
97. Miravitlles M, Marín A, Monsó E, et al. Colour of sputum is a marker for bacterial colonisation in chronic obstructive pulmonary disease. Respir Res 2010, 11:58.
98. Erb-Downward JR, Thompson DL, Han MK, et al. Analysis of the lung microbiome in the "healthy" smoker and in COPD. PLoS One 2011, 6:e16384.
99. Sze MA, Dimitriu PA, Hayashi S, et al. The lung tissue microbiome in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2012, 185:1073-1080.
100. Hilty M, Burke C, Pedro H, et al. Disordered microbial communities in asthmatic airways. PLoS One 2010, 5:e8578.
101. Pragman AA, Kim HB, Reilly CS, Wendt C, Isaacson RE The lung microbiome in moderate and severe chronic obstructive pulmonary disease. PLoS One 2012, 7:e47305.
102. Dickson RP, Erb-Downward JR, Huffnagle GB Towards an ecology of the lung: new conceptual models of pulmonary microbiology and pneumonia pathogenesis. Lancet Respir Med 2014, 2:238-246.
103. Yoon YK, Yang KS, Sohn JW, Lee CK, Kim MJ Impact of preceding respiratory viral infections on the clinical severity of patients with pneumococcal pneumonia. Influenza Other Respir Viruses 2014, published online June 24. http://dx.doi.org/10.1111/irv.12265.
104. Mallia P, Footitt J, Sotero R, et al. Rhinovirus infection induces degradation of antimicrobial peptides and secondary bacterial infection in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2012, 186:1117-1124.
105. Molyneaux PL, Mallia P, Cox MJ, et al. Outgrowth of the bacterial airway microbiome after rhinovirus exacerbation of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2013, 188:1224-1231.
106. Oliver BG, Lim S, Wark P, et al. Rhinovirus exposure impairs immune responses to bacterial products in human alveolar macrophages. Thorax 2008, 63:519-525.
107. Jamieson AM, Yu S, Annicelli CH, Medzhitov R Influenza virus-induced glucocorticoids compromise innate host defense against a secondary bacterial infection. Cell Host Microbe 2010, 7:103-114.
108. Jarad NA, Wedzicha JA, Burge PS, Calverley PM An observational study of inhaled corticosteroid withdrawal in stable chronic obstructive pulmonary disease. Respir Med 1999, 93:161-166. the ISOLDE Study Group.
109. Wouters EF, Postma DS, Fokkens B, et al. Withdrawal of fluticasone propionate from combined salmeterol/fluticasone treatment in patients with COPD causes immediate and sustained disease deterioration: a randomised controlled trial. Thorax 2005, 60:480-487. the COSMIC (COPD and Seretide: a Multi-Center Intervention and Characterization) Study Group.
110. van der Valk P, Monninkhof E, van der Palen J, Zielhuis G, van Herwaarden C Effect of discontinuation of inhaled corticosteroids in patients with chronic obstructive pulmonary disease: the COPE study. Am J Respir Crit Care Med 2002, 166:1358-1363.
111. Choudhury AB, Dawson CM, Kilvington HE, et al. Withdrawal of inhaled corticosteroids in people with COPD in primary care: a randomised controlled trial. Respir Res 2007, 8:93.
112. O'Brien A, Russo-Magno P, Karki A, et al. Effects of withdrawal of inhaled steroids in men with severe irreversible airflow obstruction. Am J Respir Crit Care Med 2001, 164:365-371.
113. Lapperre TS, Snoeck-Stroband JB, Gosman MM, et al. Effect of fluticasone with and without salmeterol on pulmonary outcomes in chronic obstructive pulmonary disease: a randomized trial. Ann Intern Med 2009, 151:517-527. the Groningen Leiden Universities Corticosteroids in Obstructive Lung Disease Study Group.
114. Sin DD, Tashkin D, Zhang X, et al. Budesonide and the risk of pneumonia: a meta-analysis of individual patient data. Lancet 2009, 374:712-719.
115. Halpin DM, Gray J, Edwards SJ, Morais J, Singh D Budesonide/formoterol vs. salmeterol/fluticasone in COPD: a systematic review and adjusted indirect comparison of pneumonia in randomised controlled trials. Int J Clin Pract 2011, 65:764-774.
116. Cheng SL, Wang HC, Cheng SJ, Yu CJ Elevated placenta growth factor predicts pneumonia in patients with chronic obstructive pulmonary disease under inhaled corticosteroids therapy. BMC Pulm Med 2011, 11:46.
117. Suissa S Number needed to treat in COPD: exacerbations versus pneumonias. Thorax 2013, 68:540-543.
118. Rossi A, Guerriero M, Corrado A Withdrawal of inhaled corticosteroids can be safe in COPD patients at low risk of exacerbation: a real-life study on the appropriateness of treatment in moderate COPD patients (OPTIMO). Respir Res 2014, 15:77.
119. Magnussen H, Disse B, Rodriguez-Roisin R, et al. Withdrawal of inhaled glucocorticoids and exacerbations of COPD. New Engl J Med 2014, published online Sept 8. 10.1056/NEJMoa1407154.
120. Vestbo J, Sørensen T, Lange P, Brix A, Torre P, Viskum K Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 1999, 353:1819-1823.
121. Dalby C, Polanowski T, Larsson T, Borgström L, Edsbäcker S, Harrison TW The bioavailability and airway clearance of the steroid component of budesonide/formoterol and salmeterol/fluticasone after inhaled administration in patients with COPD and healthy subjects: a randomized controlled trial. Respir Res 2009, 10:104.
122. Science medicines health European Medicines Agency, (accessed Aug 22, 2014). http://www.ema.europa.eu/ema/.
123. Vestbo J, Prescott E, Almdal T, et al. Body mass, fat-free body mass, and prognosis in patients with chronic obstructive pulmonary disease from a random population sample: findings from the Copenhagen City Heart Study. Am J Respir Crit Care Med 2006, 173:79-83.
124. Hawdon N, Biman B, McCready W, et al. Antibody against Haemophilus influenzae protein D in patients with chronic conditions causing secondary immunodeficiency. Vaccine 2012, 30:1235-1238.
125. Make B, Dutro MP, Paulose-Ram R, Marton JP, Mapel DW Undertreatment of COPD: a retrospective analysis of US managed care and Medicare patients. Int J Chron Obstruct Pulmon Dis 2012, 7:1-9.
126. Gulmez SE, Holm A, Frederiksen H, Jensen TG, Pedersen C, Hallas J Use of proton pump inhibitors and the risk of community-acquired pneumonia: a population-based case-control study. Arch Intern Med 2007, 167:950-955.
127. Quraishi SA, Bittner EA, Christopher KB, Camargo CA Vitamin D status and community-acquired pneumonia: results from the third National Health and Nutrition Examination Survey. PLoS One 2013, 8:e81120.
128. Gross RD, Atwood CW, Ross SB, Olszewski JW, Eichhorn KA The coordination of breathing and swallowing in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2009, 179:559-565.